Skip to main content

Table 1 Overview of the NP properties

From: Encapsulation of the dual FLAP/mPEGS-1 inhibitor BRP-187 into acetalated dextran and PLGA nanoparticles improves its cellular bioactivity

NP formulation After purification After lyophilization EE (%) LC (%) PVA (%)
dH (nm) PDI dH (nm) PDI ζ (mV)
Acdex 210 ± 26 0.17 ± 0.07 211 ± 35 0.26 ± 0.09 − 12 ± 2 0.01 ± 0.000
Acdex[BRP-187] 196 ± 51 0.16 ± 0.11 178 ± 26 0.13 ± 0.07 − 13 ± 8 59 ± 23 1.7 ± 0.6 0.01 ± 0.000
Acdex-RhodB[BRP-187] 163 ± 15 0.20 ± 0.06 189 ± 37 0.28 ± 0.11 − 24 ± 2 67 ± 10 2.0 ± 0.3 n.m.
PLGA 124 ± 6 0.06 ± 0.03 130 ± 2 0.09 ± 0.03 − 20 ± 2 0.02 ± 0.002
PLGA[BRP-187] 153 ± 41 0.17 ± 0.14 158 ± 35 0.12 ± 0.06 − 15 ± 3 76 ± 22 2.2 ± 0.6 0.03 ± 0.002
PLGA-DY635 143 ± 3 0.08 ± 0.03 154 ± 5 0.15 ± 0.02 − 20 ± 1 0.02 ± 0.006
PLGA-DY635[BRP-187] 153 ± 2 0.12 ± 0.01 168 ± 9 0.19 ± 0.05 − 19 ± 1 87 ± 6 2.5 ± 0.2 0.02 ± 0.002
  1. Concentration of NPs used for the PVA assay was 3 mg mL−1. SD for all measurements n ≥ 3. n.m.–not measured
  2. dH Hydrodynamic diameter obtained by DLS measurements. EE encapsulation efficiency. LC loading capacity